PE20090682A1 - Secuencias peptidicas y composiciones - Google Patents
Secuencias peptidicas y composicionesInfo
- Publication number
- PE20090682A1 PE20090682A1 PE2008001614A PE2008001614A PE20090682A1 PE 20090682 A1 PE20090682 A1 PE 20090682A1 PE 2008001614 A PE2008001614 A PE 2008001614A PE 2008001614 A PE2008001614 A PE 2008001614A PE 20090682 A1 PE20090682 A1 PE 20090682A1
- Authority
- PE
- Peru
- Prior art keywords
- sequences
- lymphocytes
- polypeptidic
- residues
- salival
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/858—Proteins from animals other than mammals or birds insects; venom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION POLIPEPTIDICA, CONSTRUCCION POLIPEPTIDICA Y UNA CONSTRUCCION DE ACIDO NUCLEICO QUE CONTIENE DE 2 A 12 POLIPEPTIDOS SELECCIONADOS DE i) LAS SECUENCIAS SEQ ID 1-6, 20, 28, 30-32, 35, ENTRE OTROS, O DE LAS SUBSECUENCIAS DE ESTAS SECUENCIAS QUE TIENEN 7 O MAS AMINOACIDOS; ii) LAS SECUENCIAS DEFINIDAS POR LOS RESIDUOS AMINOACIDOS DE LA PROTEINA SALIVAL DE UN ARTROPODO TALES COMO LOS RESIDUOS DE AMINOACIDOS 2-33, RESIDUOS 2-26, RESIDUOS 2-25, ENTRE OTROS, O DE LAS SUBSECUENCIAS DE ESTAS SECUENCIAS QUE TIENEN 7 O MAS AMINOACIDOS; O iii) LAS SECUENCIAS POLIPEPTIDICAS QUE TENGAN 85% O MAS DE HOMOLOGIA CON UNA O MAS DE LAS SECUENCIAS DE i) O ii). DONDE DICHOS POLIPEPTIDOS SON EPITOPOS DE LINFOCITOS T CITOTOXICOS, LINFOCITOS T COLABORADORES Y LINFOCITOS B, SIENDO INMUNOGENICOS CONTRA PROTEINAS SALIVALES DE ARTROPODOS HEMATOFAGOS TALES COMO MOSQUITOS, GARRAPATAS, ACAROS, PULGAS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES TRANSMITIDAS POR ARTROPODOS TALES COMO MALARIA, FILARIASIS, TRIPANOSOMIASIS, DENGUE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0717864.3A GB0717864D0 (en) | 2007-09-13 | 2007-09-13 | Peptide sequences and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090682A1 true PE20090682A1 (es) | 2009-06-22 |
Family
ID=38658898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001614A PE20090682A1 (es) | 2007-09-13 | 2008-09-15 | Secuencias peptidicas y composiciones |
Country Status (25)
Country | Link |
---|---|
US (2) | USRE47222E1 (es) |
EP (4) | EP2182972A2 (es) |
JP (3) | JP2010539127A (es) |
CN (1) | CN101815526B (es) |
AR (1) | AR068428A1 (es) |
AU (1) | AU2008297213B2 (es) |
BR (1) | BRPI0816330A2 (es) |
CA (1) | CA2699467A1 (es) |
CL (1) | CL2008002727A1 (es) |
CO (1) | CO6270336A2 (es) |
DK (1) | DK2783694T3 (es) |
ES (1) | ES2670859T3 (es) |
GB (1) | GB0717864D0 (es) |
HU (1) | HUE038953T2 (es) |
MX (1) | MX2010002025A (es) |
NO (1) | NO2783694T3 (es) |
PE (1) | PE20090682A1 (es) |
PL (1) | PL2783694T3 (es) |
PT (1) | PT2783694T (es) |
RU (1) | RU2466737C2 (es) |
SG (1) | SG187401A1 (es) |
TR (1) | TR201807414T4 (es) |
TW (1) | TWI548646B (es) |
WO (1) | WO2009034041A2 (es) |
ZA (1) | ZA201000914B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2576280A1 (en) * | 2004-08-13 | 2006-02-16 | Barry J. Marshall | Helicobacter pylori-based delivery system |
EP2191849B1 (en) * | 2007-09-26 | 2018-08-01 | National Cerebral and Cardiovascular Center | Drug for suppressing pathogen occurring in vivo |
WO2009131730A2 (en) * | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
JP5344558B2 (ja) | 2008-10-31 | 2013-11-20 | 国立大学法人 東京医科歯科大学 | カチオン性ナノゲルを用いる粘膜ワクチン |
FR2955393B1 (fr) * | 2010-01-18 | 2015-12-11 | Inst Rech Developpement Ird | Methode pour evaluer l'efficacite de strategies de lutte anti-vectorielle dans le controle du paludisme et des arboviroses |
KR101297037B1 (ko) * | 2010-03-26 | 2013-08-14 | 숙명여자대학교산학협력단 | 혈관신생촉진용 펩타이드 및 이의 용도 |
MX2015011257A (es) * | 2013-03-08 | 2015-11-16 | Taiho Pharmaceutical Co Ltd | Peptido novedoso que tiene 5 epitopos de linfocitos t citotoxicos enlazados. |
US10898555B2 (en) * | 2013-07-02 | 2021-01-26 | Japanese Foundation For Cancer Research | Cellular immunity inducing vaccine |
PT3061771T (pt) | 2013-10-21 | 2020-05-06 | Taiho Pharmaceutical Co Ltd | Novo péptido unido a quatro epitopos ctl |
CN104356216B (zh) * | 2014-10-09 | 2017-03-01 | 昆明医科大学 | 版纳绳蚋防御肽SibaDef及其基因和应用 |
US11452769B2 (en) | 2015-02-02 | 2022-09-27 | Yale University | Mosquito saliva protein malaria vaccine |
US9913903B2 (en) * | 2015-08-06 | 2018-03-13 | Grifols Worldwide Operations Limited | Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM |
US10570194B2 (en) | 2015-08-06 | 2020-02-25 | Grifols Worldwide Operations Limited | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
JP6893765B2 (ja) * | 2016-07-15 | 2021-06-23 | 森山 雅美 | 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤 |
CN107236028B (zh) * | 2017-07-05 | 2020-12-04 | 贵州医科大学 | 白纹伊蚊唾液34K2重组蛋白在DENV2感染HaCaT细胞中的应用 |
EP4013411A4 (en) * | 2019-08-13 | 2023-08-16 | Tata Consultancy Services Limited | PREDIABETES RISK ASSESSMENT SYSTEM AND METHODOLOGY |
WO2021028846A2 (en) * | 2019-08-13 | 2021-02-18 | Tata Consultancy Services Limited | System and method for assessing the risk of colorectal cancer |
KR102615021B1 (ko) * | 2021-10-14 | 2023-12-20 | 주식회사 메디트 | 3차원 스캐너의 스캔 이미지 정렬 방법, 장치 및 명령을 기록한 기록매체 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1572968B1 (en) * | 2002-10-29 | 2009-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
-
2007
- 2007-09-13 GB GBGB0717864.3A patent/GB0717864D0/en not_active Ceased
-
2008
- 2008-09-05 MX MX2010002025A patent/MX2010002025A/es active IP Right Grant
- 2008-09-05 SG SG2012095782A patent/SG187401A1/en unknown
- 2008-09-05 EP EP08803793A patent/EP2182972A2/en not_active Withdrawn
- 2008-09-05 CN CN200880106321.2A patent/CN101815526B/zh not_active Expired - Fee Related
- 2008-09-05 ES ES14162925.3T patent/ES2670859T3/es active Active
- 2008-09-05 EP EP11178673A patent/EP2407172A1/en not_active Withdrawn
- 2008-09-05 WO PCT/EP2008/061824 patent/WO2009034041A2/en active Application Filing
- 2008-09-05 TR TR2018/07414T patent/TR201807414T4/tr unknown
- 2008-09-05 DK DK14162925.3T patent/DK2783694T3/en active
- 2008-09-05 US US15/469,016 patent/USRE47222E1/en active Active
- 2008-09-05 HU HUE14162925A patent/HUE038953T2/hu unknown
- 2008-09-05 JP JP2010524469A patent/JP2010539127A/ja active Pending
- 2008-09-05 PT PT141629253T patent/PT2783694T/pt unknown
- 2008-09-05 BR BRPI0816330 patent/BRPI0816330A2/pt not_active Application Discontinuation
- 2008-09-05 EP EP12177189.3A patent/EP2567706A3/en not_active Withdrawn
- 2008-09-05 CA CA2699467A patent/CA2699467A1/en not_active Abandoned
- 2008-09-05 US US12/677,682 patent/US8986703B2/en not_active Ceased
- 2008-09-05 NO NO14162925A patent/NO2783694T3/no unknown
- 2008-09-05 PL PL14162925T patent/PL2783694T3/pl unknown
- 2008-09-05 EP EP14162925.3A patent/EP2783694B1/en active Active
- 2008-09-05 RU RU2010114597/15A patent/RU2466737C2/ru active IP Right Revival
- 2008-09-05 AU AU2008297213A patent/AU2008297213B2/en active Active
- 2008-09-10 TW TW097134650A patent/TWI548646B/zh not_active IP Right Cessation
- 2008-09-12 CL CL2008002727A patent/CL2008002727A1/es unknown
- 2008-09-12 AR ARP080103971A patent/AR068428A1/es not_active Application Discontinuation
- 2008-09-15 PE PE2008001614A patent/PE20090682A1/es not_active Application Discontinuation
-
2010
- 2010-02-08 ZA ZA2010/00914A patent/ZA201000914B/en unknown
- 2010-04-13 CO CO10042686A patent/CO6270336A2/es not_active Application Discontinuation
-
2013
- 2013-06-10 JP JP2013122060A patent/JP5981883B2/ja active Active
-
2016
- 2016-01-04 JP JP2016000251A patent/JP6227018B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
CL2021002464A1 (es) | Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea. | |
PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
SMT201300093B (it) | Formulazioni di vwf ricombinante liofilizzate | |
AR069989A1 (es) | Formulaciones de vwf recombinantes | |
AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
PE20140160A1 (es) | Polipeptidos de relaxina modificados y sus usos | |
AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
PE20121561A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
AR078374A1 (es) | Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |